ERX1000 / ERX Pharmaceuticals - LARVOL DELTA

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: ERX Pharmaceuticals | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity • LEP

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: ERX Pharmaceuticals | Trial completion date: Nov 2022 ➔ Jun 2023 | Trial primary completion date: Nov 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity • LEP

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: ERX Pharmaceuticals | Trial completion date: Mar 2022 ➔ Nov 2022 | Trial primary completion date: Mar 2022 ➔ Nov 2022

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity • LEP

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: ERX Pharmaceuticals; Trial completion date: Oct 2021 ➔ Mar 2022; Trial primary completion date: Oct 2021 ➔ Mar 2022

Clinical • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity • LEP

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: ERX Pharmaceuticals

Clinical • New P1 trial • Genetic Disorders • Obesity • LEP